国际妇产科联盟2023版子宫内膜癌分期的细化及临床意义  

The updation and clinical significance of 2023 FIGO staging for endometrial cancer

作　　者：胡元晶[1] 李娜[1] Hu Yuanjing;Li Na(Department of Gynecology Oncology,Tianjin Central Hospital of Obstetrics and Gynecology,Tianjin 300100,China)

机构地区：[1]天津市中心妇产科医院妇瘤科,天津300100

出　　处：《中华医学杂志》2025年第8期569-577,共9页National Medical Journal of China

基　　金：国家临床重点专科专病队列研究(GJZDZKZBDL2022-01);天津市教委科研计划项目(医学融合专项)(2023YXZD06);天津市医学重点学科(专科)建设项目(TJYXZDXK-043A)。

摘　　要：子宫内膜癌的准确分期对于患者治疗方式选择和预后判断至关重要。国际妇产科联盟(FIGO)2023版分期在2009版分期的基础上进行了更新,同时考虑了肿瘤组织类型、组织分级、淋巴脉管间隙浸润、低体积淋巴结转移及分子分型等。然而,新分期的进一步细化对真实世界临床诊疗的指导意义并未十分明确,因此,本文集中对FIGO 2023版分期的细化要点及临床应用进行论述,阐述"新""旧"分期系统之间的差异及其临床意义,旨在进一步提高子宫内膜癌的精准诊断及治疗,为子宫内膜癌的临床诊疗提供实际性指导意见。Accurate staging is crucial for the treatment and prognosis of patients with endometrial cancer.Based on the 2009 staging system,the International Federation of Gynecology and Obstetrics(FIGO)published updated staging system in 2023,incorporating factors such as tumor tissue type,histological grading,lymphovascular space invasion,low-volume lymph node metastasis and molecular profiling.However,the real world clinical application value of the new staging is still unclear.Therefore,this review focused on the updation details and discussed the clinical significance of FIGO 2023 staging system,comparing the difference and the clinical practice impact between the"new"and"old"staging systems.Through this review,it is expected that the accurate diagnosis and treatment of endometrial cancer could be improved,and practical guidance for the clinical diagnosis and treatment of endometrial cancer would be provided.

关 键 词：癌 子宫内膜样 国际妇产科联盟2023版分期 淋巴脉管间隙浸润 低体积淋巴结转移 分子分型 

分 类 号：R737.33[医药卫生—肿瘤]